1 option
Pharmacoeconomic review report : (AVIR Pharma Inc.) : indication : for the induction of clinicopathologic remission in adults with eosinophilic esophagitis. Budesonide (Jorveza) / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Language:
- English
- Subjects (All):
- Drug stability.
- Physical Description:
- 1 online resource
- Edition:
- Version: final.
- Place of Publication:
- Ottawa : Canadian Agency for Drugs and Technologies in Health, 2020.
- Summary:
- The CADTH clinical review findings indicate that Budesonide 1 mg is effective for inducing clinicopathologic remission in patients with active eosinophilic esophagitis (EoE) after six weeks of treatment, though the results are more pronounced for clinicohistologic remission than for the symptomatic remission component. The CADTH clinical review also noted uncertainty in the meaningfulness of the observed improvement in health-related quality of life. No information was available on the comparative effectiveness of Budesonide 1 mg with treatments that are currently used for EoE in Canada.
- Notes:
- Description based on publisher supplied metadata and other sources.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.